Sector News

Philips to unload Lumileds lighting biz to Apollo for $2B

December 12, 2016
Life sciences

Philips is selling a majority stake of its lighting business, Lumileds, to Apollo Global Management for $2 billion, including debt. The deal comes nearly a year after the company’s bid to offload Lumileds to a Chinese firm fell through due to pressure from U.S. regulators.

The deal will see Apollo picking up an 80.1% stake in Lumileds, with Philips holding onto the remaining 19.9%, according to a statement. While it values the lighting and automotive business at $2 billion, Philips expects to pick up about $1.5 billion in cash. The transaction is slated to close in the first half of 2017, subject to regulatory approval.

In January, the Committee on Foreign Investment in the United States nixed Philips’ sale of Lumileds to China’s GO Scale Capital for national security reasons. At the time, Philips stood to gain $2.8 billion in cash. The current deal offers the unit at a discount, but may have a better chance at success since Apollo is U.S.-based, Philips CEO Frans van Houten told Bloomberg.

“With this transaction, we will be completing an important phase of the transformation of our portfolio and I am satisfied that in the Apollo managed funds we have found the right owner for Lumileds,” van Houten said in the statement. “In line with our strategic focus on health technology, Lumileds has been operating as a standalone company within Philips since early 2015. With Apollo managed funds acquiring a majority interest in Lumileds and partnering with Philips, Lumileds is now well-positioned for further growth and value creation, building on its robust innovation pipeline, technology leadership and strong customer base.”

Philips has been plotting to shift into health tech for years, first saying in September 2014 that it would hive off its Lighting business through an IPO or a sale. Lumileds was created in 2014 as a standalone company that supplies lamps to the auto industry. Philips’ general Lighting unit spun off earlier this year, raising $839 million in an IPO that valued the business at nearly $3 billion.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.